Double blind trial of recombinant human erythropoietin in preterm infants.
نویسندگان
چکیده
منابع مشابه
Recombinant human erythropoietin improves neurological outcomes in very preterm infants
OBJECTIVE To evaluate the efficacy and safety of repeated low-dose human recombinant erythropoietin (rhEPO) in the improvement of neurological outcomes in very preterm infants. METHODS A total of 800 infants of ≤32-week gestational age who had been in an intensive care unit within 72 hours after birth were included in the trial between January 2009 and June 2013. Preterm infants were randomly...
متن کاملRecombinant erythropoietin and blood transfusion in selected preterm infants.
OBJECTIVES To comprehensively identify preterm infants likely to require blood transfusion and to investigate the effectiveness of recombinant erythropoietin in this high risk subgroup. DESIGN Double blind randomised controlled trial. SETTING Neonatal Intensive Care Unit, Middlemore Hospital, Auckland, New Zealand. PATIENTS Preterm infants < 33 weeks gestation and < 1700 g birth weight me...
متن کاملEffects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants.
OBJECTIVE Early recombinant erythropoietin therapy and iron therapy would decrease the need for red blood cells transfusions and prevents anemia of prematurity. METHODS Fifty-eight preterm infants in newborn services at Ghaem Medical Center randomly were assigned, among them 18 patients were excluded. A total of 40 preterm infants with gestational age 28-34 weeks, birth weight 1000-1750 g fol...
متن کاملIron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants.
AIMS To determine whether iron supplementation would enhance erythropoiesis in preterm infants treated with high doses of human recombinant erythropoietin (r-HuEPO). METHODS Sixty three preterm infants were randomly allocated at birth to one of three groups to receive: r-HuEPO alone, 1200 IU/kg/week (EPO); or r-HuEPO and iron, 1200 IU/kg/week of r-HuEPO plus 20 mg/kg/week of intravenous iron ...
متن کاملEfficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial.
OBJECTIVE To determine whether the administration of recombinant human erythropoietin (rHuEPO) to critically ill patients in the intensive care unit (ICU) would reduce the number of red blood cell (RBC) transfusions required. DESIGN A prospective, randomized, double-blind, placebo-controlled, multicenter trial. SETTING ICUs at three academic tertiary care medical centers. PATIENTS A total...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Disease in Childhood
سال: 1993
ISSN: 0003-9888,1468-2044
DOI: 10.1136/adc.68.3_spec_no.291